A clinical trial commenced in 2016 comparing andecaliximab (also known as GS-5745), which is an MMP9 inhibitor, as monotherapy and in combination with anti-cancer agents in Japanese participants with gastric or gastroesophageal junction adenocarcinoma is currently awaiting results (ClinicalTrials.gov, NCT02862535). The gene discussed is MMP9; the disease is gastroesophageal junction adenocarcinoma.